BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9875666)

  • 1. Graft-versus-host disease following second syngeneic stem cell transplantation for relapsed chronic myeloid leukemia.
    Reiter E; Greinix HT; Mitterbauer G; Fischer G; Keil F; Mannhalter C; Rabitsch W; Schwarzinger I; Worel N; Lechner K; Kalhs P
    Ann Hematol; 1998 Dec; 77(6):283-6. PubMed ID: 9875666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
    Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
    Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation.
    Bär BM; Schattenberg A; Mensink EJ; Geurts Van Kessel A; Smetsers TF; Knops GH; Linders EH; De Witte T
    J Clin Oncol; 1993 Mar; 11(3):513-9. PubMed ID: 8445426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Hertenstein B; Wiesneth M; Novotny J; Bunjes D; Stefanic M; Heinze B; Hübner G; Heimpel H; Arnold R
    Transplantation; 1993 Nov; 56(5):1114-8. PubMed ID: 8249110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful one antigen mismatched bone marrow transplant for chronic myeloid leukemia (CML) after two failed syngeneic transplants.
    Manna A; Bacigalupo A; Palazzo G; Amurri B; Maggi A; Mazza P
    Bone Marrow Transplant; 1999 May; 23(10):1085-6. PubMed ID: 10373077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose.
    Drobyski WR; Keever CA; Roth MS; Koethe S; Hanson G; McFadden P; Gottschall JL; Ash RC; van Tuinen P; Horowitz MM
    Blood; 1993 Oct; 82(8):2310-8. PubMed ID: 8400284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia.
    Reiter E; Greinix HT; Keil F; Brugger S; Rabitsch W; Schulenburg A; Mannhalter C; Schwarzinger I; Worel N; Volc-Platzer B; Fischer G; Dieckmann K; Hinterberger W; Schneider B; Haas OA; Geissler K; Kalhs P
    Ann Hematol; 1999 Nov; 78(11):507-13. PubMed ID: 10602894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemia: management of relapse after allogeneic bone marrow transplantation.
    Kumar L
    J Clin Oncol; 1994 Aug; 12(8):1710-7. PubMed ID: 8040682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of chronic myelogenous leukemia 12 years after allogeneic marrow transplantation: successful second transplantation with allogeneic peripheral blood progenitor cells.
    Reiter E; Rabitsch W; Greinix HT; Keil F; Mitterbauer G; Hinterberger W; Haas OA; Lechner K; Kalhs P
    Leuk Lymphoma; 2000 Dec; 40(1-2):215-8. PubMed ID: 11426624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
    Gaiger A; Lion T; Kalhs P; Mitterbauer G; Henn T; Haas O; Födinger M; Kier P; Forstinger C; Quehenberger P
    Leukemia; 1993 Nov; 7(11):1766-72. PubMed ID: 8231244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected late graft failure 9 months after HLA-identical bone marrow transplant (BMT) for chronic myeloid leukemia (CML): treatment with a second BMT.
    Gil-Fernández JJ; Arranz R; Cámara R; Alegre A; Figuera A; Fernández-Rañada JM
    Haematologica; 1998 Mar; 83(3):285-7. PubMed ID: 9580418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
    Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
    Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
    Porter DL; Roth MS; McGarigle C; Ferrara JL; Antin JH
    N Engl J Med; 1994 Jan; 330(2):100-6. PubMed ID: 8259165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
    Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
    Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation.
    Browett PJ; Nelson J; Tiwari S; Van de Water NS; May S; Palmer SJ
    Bone Marrow Transplant; 1994 Oct; 14(4):641-4. PubMed ID: 7858542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.